Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs

European Neuropsychopharmacology

Volumn 16, Issue 8, 2006, Pages 592-600

  Gruber, Susanne H M ^a   Nomikos, George G ^b   Mathé, Aleksander A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic drugs; d Amphetamine; Microdialysis; Neuropeptide Y; Neurotensin; Schizophrenia; Striatum

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROPEPTIDE Y; NEUROTENSIN; RISPERIDONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG EFFECT; FRONTAL CORTEX; HIPPOCAMPUS; MALE; NONHUMAN; OCCIPITAL CORTEX; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXTRACELLULAR FLUID; HALOPERIDOL; MALE; MICRODIALYSIS; NEUROPEPTIDE Y; NEUROTENSIN; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RISPERIDONE; TIME FACTORS;

EID: 33750810192     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.01.009     Document Type: Article

References (61)

1. Adams D.H., Hanson G.R., and Keefe K.A. Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience 102 (2001) 843-851
2. Aravagiri M., Marder S.R., Wirshing D., and Wirshing W.C. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatria 31 (1998) 102-109
3. Betancur C., Rostène W., and Bérod A. Chronic cocaine increases neurotensin gene expression in the shell of the nucleus accumbens and in discrete regions of the striatum. Mol. Brain Res. 44 (1997) 334-340
4. Binder E.B., Kinkead B., Owens M.J., Kilts C.D., and Nemeroff C.B. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J. Neurosci. 21 (2001) 601-608
5. Boules M., Warrington L., Fauq A., McCormick D., and Richelson E. A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 426 (2001) 73-76
6. Connell P.H. Amphetamine Psychosis (1958), Chapman and Hill, London
7. Csernansky J.G., Murphy G.M., and Faustman W.O. Limbic/mesolimbic connections and the pathogenesis of schizophrenia. Biol. Psychiatry 15 30:4 (1991) 383-400
8. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
9. Drumheller A., Buali S.M., Fournier A., St-Pierre S., and Lolicoeur F.B. Neurochemical effects of neuropeptide Y (NPY) and NPY2-36. Neuropeptides 27 (1994) 291-296
10. Ervin G.N., Birkemo L.S., Nemeroff C.B., and Prange Jr. A.J. Neurotensin blocks certain amphetamine-induced behaviours. Nature 7 (1981) 73-76
11. Glowinski J., and Iversen L.L. Regional studies of catecholamines in the rat brain: the disposition of (3H) norepinerphine, (3H) dopamine and (3H) dopa in various regions of the brain. J. Neurochem. 13 (1966) 655-669
12. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res. Rev. 31 (2000) 330-341
13. Gray J.A., Feldon J., Rawlins J.N.P., Hemsley D.R., and Smith A.D. The neuropsychology of schizophrenia. Behav. Brain Sci. 14 (1991) 1-84
14. Gruber S.H.M., and Mathé A.A. Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum. J. Neurosci. Res. 61 (2000) 458-463
15. Gruber S.H.M., Nomikos G.G., and Mathé A.A. Effects of haloperidol and risperidone on neurotensin levels in brain regions and release in the ventral striatum of the rat. Neuropsychopharmacology 26 (2002) 595-604
16. 2 receptors. J. Neurosci. Res. 69 (2002) 133-139
17. Gygi S.P., Gibb J.W., and Hanson G.R. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J. Pharmacol. Exp. Ther. 270 (1994) 192-197
18. Heilig M., Vècséi L., Wahlested C., Alling Ch., and Widerlöw E. Effects of centrally administrated neuropeptide Y (NPY) and NPY13-36 on the brain monoaminergic systems of the rat. J. Neural Transm. 79 (1990) 193-208
19. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjögren M., Asberg M., Ekman R., Wahlestedt C., and Ågren H. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J. Psychiatr. Res. 38 (2004) 113-121
20. Huang W., and Hanson GR. Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems. Eur. J. Pharmacol. 332 (1997) 15-21
21. Husum H., Mikkelsen J.D., Hogg S., Mathé A.A., and Mörk A. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 39 (2000) 1463-1473
22. Husum H., Gruber S.H.M., Bolwig T.G., and Mathé A.A. Extracellular levels of NPY in the dorsal hippocampus of freely moving rats are markedly elevated following a single electroconvulsive stimulation, irrespective of anticonvulsive Y1 receptor blockade. Neuropeptides 36 (2002) 363-369
23. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hupofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
24. Jimenez-Vasquez P.A., Overstreet D.H., and Mathé A.A. Neuropeptide Y in male and female brains of flinders sensitive line, a rat model of depression. Effects of electroconvulsive stimuli. J. Psychiatr. Res. 34 (2000) 405-412
25. Jiménez-Vasquez P.A., Mathé A.A., Thomas J.D., Riley E.P., and Ehlers C.L. Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Dev. Brain Res. 131 (2001) 149-152
26. Joliceur F.B., Gange M.A., Rivest R., Drumheller A., and St Pierre S. Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res. Bull. 32 (1993) 487-491
27. Kalivas P.W., and Duffy P. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J. Neurosci. 10 (1990) 2940-2949
28. Kerkerian L., Bosler O., Pelletier G., and Nieoullon A. Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci. Lett. 66 (1986) 106-112
29. Kerkerian-LeGoff L., Forni C., Samuel D., Block A., Dusticier N., and Nieoullon A. Intracerebroventricular administration of neuropeptide Y affects parameters of dopamine, glutamate and GABA activities in the rat striatum. Brain Res. 28 (1992) 187-193
30. Konkoy C.S., Waters S.M., and Davis T.P. Acute administration of neuroleptics decreases neurotensin metabolism on intact, regional rat brain slices. J. Pharmacol. Exp. Ther. 269 (1994) 555-563
31. Kuczenski R., and Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J. Neurosci. 9 (1989) 2051-2065
32. Laruelle M., Abi-Dargham A., and van Dyck C.H. Single photon emission computerised tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. 93 (1996) 9235-9240
33. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., and Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 46 (1999) 56-72
34. Levant B., Garimelli B., Shafer RA., and Merchant K.M. Increased levels of proneurotensin/neuromedin mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride. Neuropsychopharmacology 21 (1999) 304-311
35. Mathé A.A. Neuropeptides and electroconvulsive treatment. J. ECT 15 (1999) 60-75
36. Mathé A.A., Stenfors C., Brodin E., and Theodorsson E. Neuropeptides in brain: effects of microwave irradiation and decapitation. Life Sci. 46 (1990) 287-293
37. Mathé A.A., Rudorfer W.V., Stenfors C., Manji H.K., Potter W.Z., and Theodorsson E. Effects of electroconvulsive treatment on somatostatin, neuropeptide Y, endothelin, and neurokinin A concentrations in cerebrospinal fluid of depressed patients: a pilot study. Depression 3 (1996) 250-256
38. Mathé A.A., Jimenez P.A., Theodorsson E., and Stenfors C. Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded "depressed", Wistar, and Sprague Dawley rats. Effects of electroconvulsive stimuli. Prog. Neuro-psychopharmacol. Biol. Psychiatry 22 (1998) 529-546
39. Meng Z.H., Feldpaush D.L., and Merchant K.M. Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats. Mol. Brain Res. 61 (1998) 39-50
40. Merchant K.M., and Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc. Natl. Acad. Sci. 90 (1993) 3447-3451
41. Merchant K.M., and Miller M.A. Coexpression of neurotensin and c-fos mRNAs in rat neostriatum neurons following acute haloperidol. Mol. Brain Res. 23 (1994) 271-277
42. Merchant K.M., Dobie D.J., Filloux F.M., Totzke M., Aravagiri M., and Dorsa D.M. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J. Pharmacol. Exp. Ther. 271 (1994) 460-471
43. Nemeroff C.B., Levant B., Myers B., and Bissette G. Neurotensin: antipsychotic drugs, and schizophrenia. Ann. N.Y. Acad. Sci. 668 (1992) 147-156
44. Nikisch G., Ågren H., Eap C.B., Czernik A., Baumann P., and Mathé A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 8 (2005) 1-8
45. Obuchowicz E., and Herman Z.S. Effects of haloperidol and clozapine on neuropeptide Y-like immunoreactivity in the nucleus accumbens and striatum of rats pretreated with psychostimulants. Neuropeptides 37 (2003) 17-24
46. Obuchowicz E., and Turchan J. Clozapine decreases neuropeptide Y-like immunoreactivity and neuropeptide Y mRNA levels in rat nucleus accumbens. Eur. Neuropsychopharmacol. 9 (1999) 329-335
47. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. (1986), Academic Press, London
48. Radke J.M., Owens M.J., Ritchie J.C., and Nemeroff C.B. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. Proc. Natl. Acad. Sci. 95 (1998) 11462-11464
49. Robinson T.E., and Becker J.B. Enduring changes in brain and behaviour produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11 (1986) 157-198
50. Robledo P., Maldonado R., and Koob G.F. Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat. Brain Res. 622 (1993) 105-112
51. Rosse R.B., Collins J.P., Fay-McCarthy M., Alim T.N., Wyatt R.J., and Deutsch S.I. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychosis: a retrospective study. Clin. Neuropharmacol. 17 (1994) 359-369
52. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on social behaviour of rats. Behav. Pharmacol. 6 (1995) 55-65
53. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19 (1998) 18-25
54. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
55. Smialowska M., Bajkowska M., Przewlocka B., Maj M., Turchan J., and Przewlock R. Effects of 6-hydroxydopamine on neuropeptide Y and corticotropine-releasing factor expression in rat amygdala. Neuroscience 94 (1999) 1125-1132
56. Steinberg R., Brun P., Souilhac J., Bougault I., Leyris R., Le Fur G., and Soubrie P. Neurochemical and behavioural effects of neurotensin vs. [D-Tyr11] neurotensin on mesolimbic dopaminergic function. Neuropeptides 28 (1995) 43-50
57. Sunderland T., and Cohen B.M. Blood to brain distribution of neuroleptics. Psychiatry Res. 20 (1987) 299-305
58. Theodorsson E., Stenfors C., and Mathé A.A. Microwave irradiation increases recovery of neuropeptides from brain tissues. Peptides 11 (1990) 1191-1197
59. Thorberg S.A., and Saklad S.R. A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 16 (1996) 82-93
60. Weinberger D.R., and Lipska B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr. Res. 16 (1995) 87-110
61. Westwood S.C., and Hanson G.R. Effects of stimulants of abuse on extrapyramidal and limbic neuropeptide Y systems. J. Pharmacol. Exp. Ther. 288 (1999) 1160-1166